Clinical effect of Bevacizumab combined with albumin binding paclitaxel in the treatment of platinum resistant recurrent ovarian cancer

Abstract

Objective To explore the efficacy and safety of Bevacizumab combined with albumin binding paclitaxel in the treatment of platinum resistant recurrent ovarian cancer. Methods From June 2014 to January 2016, eighty-two recurrent ovarian cancer patients were selected in the study and randomly divided into the treatment group (41 cases) and the control group (41 cases), the control group was treated with albumin binding paclitaxel, and the treatment group was treated with Bevacizumab combined with albumin binding paclitaxel.The clinical efficacy (such as overall response rate, complete response rate, partial response rate, stability of disease, progression of disease), progression free survival(PFS), overall survival (OS)and the adverse reaction rate were compared. Results The total effective rate (ORR) of the experimental group was 85.37% (35/41), which was significantly higher than that of the control group (65.85% (27/41), and the difference was statistically significant (P=0.040). The median PFS and OS in the experimental group were 9 (1~16)months and 16 (4~26) months, significantly higher than those in the control group (6(1~13)months (HR=0.624, 95%CI: 0.367~0.899, P=0.023); 12(2~25)months(HR=0.603, 95%CI: 0.324~0.791, P=0.009); subgroup analysis showed that the median OS of patienta without metastasis in the experimental and control group were 18(8~26)months and 13 (2~25)months respectively(HR=HR=0.610, 95%CI: 0.229~1.544, P=0.291), and the median PFS was 11 (5~16)months and 8 (1~13) months (HR=0.496, 95%CI: 0.160~1.046, P=0.089), there were no significant differences; the median PFS in patients with metastasis of the experimental group and the control group were 9 (3~14)months and 6 (1~10)months (HR=0.483, 95%CI: 0.273 ~ 0.769 months, P<0.001), the median OS were 14 (4~22) months and 11 (2~20)months (HR=0.556, 95%CI: 0.197~0.569, P=0.008). There was no significant difference in the incidence of adverse reactions between the two groups (12.20%, 21.95%, P=0.240). Conclusion Compared with the treatment of albumin binding paclitaxel, in the treatment of platinum resistant recurrent ovarian cancer, the combined treatment of bevacizumab and albumin binding paclitaxel can significantly improve the clinical effect and improve the patients' survival and total survival time. Key words: Recurrent ovarian cancer; Bevacizumab; Albumin binding paclitaxel; Platinum resistance paclitaxel; Platinum resistance